The Club's top 10 things to watch in the stock market Monday

The article is dominated by deal activity, with AbbVie agreeing to buy Apogee Therapeutics for $10.9B and CRH acquiring Arcosa for $8.5B, both reinforcing M&A momentum. Analyst actions were mostly constructive: Corning's price target rose to $205 from $149, Morgan Stanley lifted Nucor to $258 and trimmed Cleveland-Cliffs to a $12.50 target with a hold downgrade, Goldman reinstated Estée Lauder at buy with a $100 target, and Wells Fargo raised targets across semiconductor equipment names including ASML, Applied Materials, KLA and Lam Research. Broader markets were steady, oil was near $76.50 per barrel, and geopolitical tensions around Iran and the Strait of Hormuz remained a backdrop.

Analysis

The most important second-order effect is that this is not a broad market tape story; it is a capital-expenditure reallocation story. AI infrastructure is still the gravity well, but the beneficiaries are shifting from the headline hyperscalers to the picks-and-shovels names with supply constraints and pricing power, while the megacaps increasingly look like funding vehicles for the buildout rather than the cleanest equity expression of it. That leaves semicap equipment, power infrastructure, and select materials names better positioned to keep compounding even if AI software sentiment cools.

M&A is becoming a visible confirmation signal for the market that biotech and industrial owners are willing to pay up for de-risked assets and installed demand. For healthcare, the Apogee deal raises the bar for private immunology assets and should keep strategic bidding pressure high, but it also reinforces that smaller clinical-stage names are being acquired for platform value rather than peak sales narratives. In industrials, infrastructure-related demand is finally translating into consolidation, which is constructive for contractors and equipment suppliers, but not all materials are equal: names tied to higher-multiple AI/data-center capex should keep outperforming commodity-exposed peers.

The steel call is more nuanced than the headline suggests: elevated prices help the group, but the market is already discounting scarcity, so the cleaner trade is into volume-sensitive beneficiaries rather than the most levered beta names. That means the setup favors Nucor over Cleveland-Cliffs on quality and balance sheet durability, while Cliffs is the cleaner short if steel prices stay high but auto demand and execution remain soft. Meanwhile, energy-price stability limits immediate upside in crude-linked equities, but the data-center power deal is a useful signal that grid constraints, gas turbines, and distributed power are becoming the bottleneck in AI expansion, which supports power-generation hardware over software multiple expansion.

Key Decisions for Investors

• Long AMAT / LRCX / ASML basket on a 1-3 month horizon; use pullbacks to add, as supply-constrained AI capex should keep estimates rising even if megacap sentiment cools. Risk/reward improves if any of the hyperscalers guide capex higher again.
• Long GEV versus short a basket of hyperscaler proxies (AMZN, META, GOOGL, MSFT) on a 2-6 month relative basis; the trade captures the idea that power infrastructure is the bottleneck, not software monetization. Stop if AI capex headlines roll over meaningfully.
• Pair long NUE / short CLF for 1-2 quarters; elevated steel pricing is supportive, but NUE has cleaner earnings quality and less downside if the market stops paying for cyclical beta. CLF is the lower-quality way to express the same macro view.
• Stay long GS as an M&A participation trade over the next 3-6 months; the mix of healthcare and industrial deal activity supports fee visibility. Trim on any broad market risk-off because the catalyst is flow-dependent, not structural.
• Use ABBV strength tactically but avoid chasing APGE unless you are playing takeover optionality in the sector; the better read-through is that strategic value in immunology is being marked up, which should help other platform assets. A basket approach is preferable to single-name event risk.